About
Our Story
Leadership
Research Partners
Our Science
ImmuX Technology
FusionX Technology
IME Cell Technology
R&D Pipeline
Publications
Media
Careers
Contact
About
Our Story
Leadership
Research Partners
Our Science
ImmuX Technology
FusionX Technology
IME Cell Technology
R&D Pipeline
Publications
Media
Careers
Contact
中文
English
Media
CD Biopharma Announces Upcoming Scientific Presentations at AACR Annual Meeting 2025
CD Biopharma Announces Upcoming Scientific Presentations at AACR Annual Meeting 2025
CD Biopharma Announces Upcoming Scientific Presentations at AACR Annual Meeting 2025
2025-03-07
09:50:00
SUZHOU, China, March 5, 2025 -- CD (Suzhou) Biopharma, an innovative biotechnology company focused o...
SUZHOU, China, March 5, 2025 -- CD (Suzhou) Biopharma, an innovative biotechnology company focused o...
SUZHOU, China, March 5, 2025 -- CD (...
CD Biopharma Achieves First Patient Dosing Milestone for Lead Program CD-001
CD Biopharma Achieves First Patient Dosing Milestone for Lead Program CD-001
CD Biopharma Achieves First Patient Dosing Milestone for Lead Program CD-001
2025-01-20
17:18:00
SUZHOU, China, January 20, 2025 - CD (Suzhou) Biopharma announced that it has successfully dosed the...
SUZHOU, China, January 20, 2025 - CD (Suzhou) Biopharma announced that it has successfully dosed the...
SUZHOU, China, January 20, 2025 - CD...
Exciting News | CD Biopharma's CD-001 Study Initiates at Lead Clinical Site
Exciting News | CD Biopharma's CD-001 Study Initiates at Lead Clinical Site
Exciting News | CD Biopharma's CD-001 Study Initiates at Lead Clinical Site
2025-01-06
13:00:00
SUZHOU, China, January 6, 2025 - CD (Suzhou) Biopharma announces that its CD-001-CT101 study was off...
SUZHOU, China, January 6, 2025 - CD (Suzhou) Biopharma announces that its CD-001-CT101 study was off...
SUZHOU, China, January 6, 2025 - CD ...
Indication Expansion: CD Biopharma's Lead Program CD-001 Receives IND Acceptance from NMPA for New Indication
Indication Expansion: CD Biopharma's Lead Program CD-001 Receives IND Acceptance from NMPA for New Indication
Indication Expansion: CD Biopharma's Lead Program CD-001 Receives IND Acceptance from NMPA for New Indication
2024-12-30
12:00:00
SUZHOU, China, Dec. 30, 2024 - CD (Suzhou) Biopharma announced that following the previous IND clear...
SUZHOU, China, Dec. 30, 2024 - CD (Suzhou) Biopharma announced that following the previous IND clear...
SUZHOU, China, Dec. 30, 2024 - CD (S...
CD Biopharma Receives IND Approval of CD-001 by the NMPA
CD Biopharma Receives IND Approval of CD-001 by the NMPA
CD Biopharma Receives IND Approval of CD-001 by the NMPA
2024-12-20
12:00:00
SUZHOU, China, Dec. 20, 2024 -- CD Biopharma, a rapidly advancing clinical-stage biotech company tha...
SUZHOU, China, Dec. 20, 2024 -- CD Biopharma, a rapidly advancing clinical-stage biotech company tha...
SUZHOU, China, Dec. 20, 2024 -- CD B...
1
2
Next
Total 2 Page
To
Page
Sure
